FDA Approves Sanofi Drug for Pediatric Stage 3 Type I Diabetes

 The U.S. Food and Drug Administration (FDA) has approved Tzield (teplizumab) injection to delay (slow down) the loss of the body’s own insulin production for pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 Type I diabetes (T1D).

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-pediatric-stage-3-type-i-diabetes